112159-16-7

Basic information

• Product Name: 2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid
• Synonyms: 2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid;2-tert-Butoxycarbonylamino-pentanedioic acid 5-methyl ester;2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid(WXC02366)
• CAS NO: 112159-16-7
• Molecular Formula: C₁₁H₁₉NO₆
• Molecular Weight: 261.27166
• Mol File: 112159-16-7.mol
• Article Data: 10

Chemical Properties

• Boiling Point: 428.4±40.0 °C(Predicted)
• Appearance: /
• Density: 1.182±0.06 g/cm3(Predicted)
• PKA: 3.82±0.10(Predicted)
• CAS DataBase Reference: 2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid(CAS DataBase Reference)
• NIST Chemistry Reference: 2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid(112159-16-7)
• EPA Substance Registry System: 2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid(112159-16-7)

Safety Data

• Hazardous Substances Data: 112159-16-7(Hazardous Substances Data)

Usage

General Description

2-([(Tert-Butoxy)Carbonyl]Amino)-5-Methoxy-5-Oxopentanoic Acid, also known as Boc-L-methionine, is a chemical compound with the molecular formula C12H21NO6. It is a derivative of the amino acid methionine, and is commonly used as a building block in peptide synthesis. Boc-L-methionine is often used in the pharmaceutical industry for the production of various drugs and medications. It is also used in research and development for the synthesis of peptides and proteins. The compound is known for its ability to protect the amino group of methionine, making it a valuable tool in the field of biochemistry and biotechnology.

Upstream product

• 6461-04-7 (R)-2-amino-5-methoxy-5-oxopentanoic acid 
• 34619-03-9 tert-butyldicarbonate 
• 24424-99-5 di-tert-butyl dicarbonate 
• 27025-22-5 D-glutamic acid-5-methyl ester; hydrochloride 
• 1499-55-4 DL-glutamic acid-5-methyl ester 
• 617-65-2 Glutamic acid 
• 187458-77-1 glutamic acid diester hydrochloride 
• 41840-28-2 S-tert-butoxycarbonyl-4,6-dimethyl-2-mercaptopyrimidine 
• 6893-26-1 D-Glutamic acid 

Downstream Products

• 1323407-86-8 3-[4-[[4-(bromomethyl)phenyl]methoxy]-1-oxo-isoindolin-2-yl]piperidine-2,6-dione 
• 76379-02-7 t-butoxycarbonyl-D-glutamic acid γ-methyl ester dicyclohexylamine salt 
• 1323405-59-9 3-(4-((4-((4-methylpiperazin-1-yl)methyl)benzyl)oxy)-1-oxoisoindolin-2-yl)piperidine-2,6-dione 
• 132245-78-4 1-benzyl-5-methyl-2-((tert-butyloxycarbonyl)amino)pentanedioate 
• 1389332-14-2 C₂HF₃O₂*C₂₇H₃₇N₉O₈ 
• 1389332-63-1 C₄₁H₅₇N₉O₁₁S 

Relevant articles and documents

Discovery of CRBN E3 Ligase Modulator CC-92480 for the Treatment of Relapsed and Refractory Multiple Myeloma

Many patients with multiple myeloma (MM) initially respond to treatment with modern combination regimens including immunomodulatory agents (lenalidomide and pomalidomide) and proteasome inhibitors. However, some patients lack an initial response to therapy (i.e., are refractory), and although the mean survival of MM patients has more than doubled in recent years, most patients will eventually relapse. To address this need, we explored the potential of novel cereblon E3 ligase modulators (CELMoDs) for the treatment of patients with relapsed or refractory multiple myeloma (RRMM). We found that optimization beyond potency of degradation, including degradation efficiency and kinetics, could provide efficacy in a lenalidomide-resistant setting. Guided by both phenotypic and protein degradation data, we describe a series of CELMoDs for the treatment of RRMM, culminating in the discovery of CC-92480, a novel protein degrader and the first CELMoD to enter clinical development that was specifically designed for efficient and rapid protein degradation kinetics.

ANTIPROLIFERATIVE COMPOUNDS AND BISPECIFIC ANTIBODY AGAINST BCMA AND CD3 FOR COMBINED USE

Provided herein is are methods of using 4-(4-(4-(((2-(2,6-dioxopiperidin-3-yl)-l- oxoisoindolin-4-yl)oxy)methyl)benzyl)piperazin-l-yl)-3-fluorobenzonitrile, or an enantiomer, a mixture of enantiomers, a tautomer, or a pharmaceutically acceptable salt thereof and a bispecific antibody specifically binding to human B cell maturation antigen (BCMA) and to human CD3e (CD3) provided herein, in treating, preventing or managing multiple myeloma.

Multifunctional diamine AGE/ALE inhibitors with potential therapeutical properties against Alzheimer's disease

An important part of pathogenesis of Alzheimer's disease (AD) is attributed to the contribution of AGE (Advanced Glycation Endproducts) and ALE (Advanced Lipid peroxidation Endproducts). In order to attenuate the progression of AD, we designed a new type of molecules that consist of two trapping parts for reactive carbonyl species (RCS) and reactive oxygen species (ROS), precursors of AGE and ALE, respectively. These molecules also chelate transition metals, the promoters of ROS formation. In this paper, synthesis of the new AGE/ALE inhibitors and evaluation of their physicochemical and biological properties (carbonyl trapping capacity, antioxidant activity, Cu2+-chelating capacity, cytotoxicity and protective effect against in?vitro MGO-induced apoptosis in the model AD cell-line PC12) are described. It is found that compounds 40b and 51e possess promising therapeutic potentials for treating AD.